Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

John Carroll

Editor & Founder

Ex-Novartis chief Joe Jimenez and his longtime colleague Mark Fishman have now ramped up their 5th biotech sub at the upstart Aditum. And once again …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

John Carroll

Editor & Founder

Sign up to read this article for free.

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Joe Jimenez and Mark Fish­man sign up their 5th drug can­di­date — and they have an­oth­er big tar­get in their crosshairs

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Joe Jimenez and Mark Fishman sign up their 5th drug candidate — and they have another big target in their crosshairs

Applied Therapeutics' rare disease drug gets a CRL

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life